Roctavian access in Pakistan: the DRAP and travel-to-treatment pathway
Medicine price: quote on request. You get a written quote for your case before you commit.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team. This page describes the personal-import-and-travel-to-treatment pathway for Roctavian for adult patients in Pakistan with severe hemophilia A who meet the eligibility profile for the AAV5 gene therapy. We frame durability honestly throughout; Roctavian is not pitched as a cure.
Ask about Roctavian in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Section 1. Quick orientation
Roctavian (valoctocogene roxaparvovec-rvox) is a one-time intravenous gene therapy for severe hemophilia A in adults, manufactured by BioMarin Pharmaceutical Inc. of San Rafael, California. The modality is an adeno-associated virus serotype 5 (AAV5) vector that delivers a B-domain-deleted human coagulation factor VIII (FVIII) transgene to hepatocytes, where the transgene drives endogenous FVIII production and partially corrects the underlying clotting defect. The US Food and Drug Administration approved Roctavian on 29 June 2023 for adults with severe hemophilia A (FVIII activity less than 1 IU/dL) who do not have pre-existing antibodies to AAV5 (detected by an FDA-approved test) and have no history of FVIII inhibitors. The European Commission granted conditional marketing authorisation on 24 August 2022. Roctavian is not registered with the Drug Regulatory Authority of Pakistan (DRAP) for commercial sale, and there is no BioMarin-certified Hemophilia Treatment Centre in Pakistan. For Pakistani adults who meet the eligibility profile, the lawful pathway is the DRAP Special Permission framework for the documentation and sample-shipment logistics combined with travel to a certified BioMarin treatment centre in the United States or European Union where the infusion is administered. The Hemophilia Patients Welfare Society Pakistan and the broader patient-advocacy network around the major haematology centres can run alongside the medical and logistics coordination. Reserve Meds coordinates eligibility verification, certified-centre booking, frozen-product logistics, the travel-and-stay framework, and the long-term monitoring handoff. Reserved for you.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Section 2. Why patients in Pakistan need Roctavian through a named-patient pathway
Pakistan has a meaningful hemophilia A patient population concentrated in family registries managed through the major haematology centres and through the Hemophilia Patients Welfare Society Pakistan (HPWS Pakistan), the principal patient-advocacy organisation supporting people with bleeding disorders across the country. The standard-of-care reality in Pakistan for severe hemophilia A is recombinant or plasma-derived FVIII prophylaxis where supply and funding permit, with emicizumab (Hemlibra) accessible through named-patient channels and limited reimbursed pathways for patients with inhibitors or where prophylactic factor coverage is constrained. Roctavian represents a categorically different option: a single intravenous infusion intended to provide multi-year freedom from prophylaxis dosing for patients who meet the eligibility profile.
The structural reasons Pakistani adults pursue Roctavian through a cross-border pathway are concrete. BioMarin has not registered Roctavian with DRAP. There is no certified Hemophilia Treatment Centre in Pakistan because BioMarin's commercial footprint in South Asia for this product is limited and the certified-centre training, AAV5 vector handling certification, infusion readiness sign-off, and outcomes warranty infrastructure have not been built locally. Patients in Pakistan who meet the eligibility profile (severe hemophilia A with FVIII activity less than 1 IU/dL, AAV5-negative on the FDA-approved companion test, no FVIII inhibitor history, no contraindicating hepatic disease) and who can self-fund or have verified third-party funding must travel to a BioMarin-qualified Hemophilia Treatment Centre in the United States or European Union for the infusion. The DRAP Special Permission framework facilitates documentation for the cross-border movement of the AAV5 antibody-test sample (the FDA-approved companion test may not be available at all Pakistani haematology labs and sample shipment abroad may require import-export documentation), for the post-infusion corticosteroid prescription if filled in Pakistan, and for any pre-infusion factor product the patient brings into Pakistan in transit. The infusion itself takes place at the certified centre abroad. Pakistan's diaspora pattern is particularly relevant here: families routinely fund specialty care by pooling resources across overseas relatives in Saudi Arabia, the UAE, the UK, the United States, and Canada, and a Roctavian case stretches that funding model to its outer limit.
Section 3. The DRAP Special Permission pathway and the BioMarin certified-centre pathway for Roctavian
DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing Division's Import and Export Section, with Drug Registration Board oversight for new product registration matters. For unregistered medicines or therapeutic-goods movements required by a specific patient, DRAP issues a Special Permission, also referred to as the No Objection Certificate (NOC) for Personal Use Import. Applications are filed through DRAP's Online Import and Export System (OIES). Reserve Meds does not file with DRAP and does not act as a Pakistani importer of record.
For Roctavian specifically, the dominant pathway is travel-and-infuse abroad rather than import-and-infuse-at-home, because BioMarin does not support infusion outside a qualified Hemophilia Treatment Centre and no such centre exists in Pakistan. The DRAP framework remains relevant for the patient's pre-infusion AAV5 antibody testing logistics (sample-shipment documentation if the FDA-approved companion test is performed abroad), for any pre-infusion factor product the patient brings into Pakistan in transit, and for the post-infusion corticosteroid prescription if filled in Pakistan rather than at the certified centre. Reserve Meds coordinates the AAV5 sample logistics, the certified-centre booking with the BioMarin RoctavianConnect programme, the patient and family travel logistics including visa documentation flagging where needed, and the handoff between the certified centre's haematology team and the Pakistani-side haematology team for post-travel monitoring.
The cell-specific clinical-justification framework for Roctavian is the gene-therapy eligibility envelope. BioMarin's RoctavianConnect handles the eligibility verification through the certified centre: confirmed severe hemophilia A with FVIII activity less than 1 IU/dL, negative AAV5 neutralising antibody titre on the FDA-approved companion test, no current or historical FVIII inhibitors confirmed through prior medical records (Bethesda titre history where available, not patient recall alone), baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) within an acceptable range, no significant fibrosis, no active hepatitis B or C, and HIV with controlled viral load if applicable. Patients who do not pass any one of these gates are not Roctavian candidates and the conversation routes back to the treating haematologist for continued FVIII prophylaxis or emicizumab. We give you a written timeline estimate for your case before you commit. the certified-centre booking is the rate-limiting layer and runs separately on a four to twelve week cadence depending on the centre's capacity.
Section 4. Where Roctavian gets infused for Pakistani patients
Roctavian is supplied only to a limited network of BioMarin-qualified Hemophilia Treatment Centres (HTCs) that have completed product-specific training, vector handling certification, and infusion readiness sign-off. There are no certified centres in Pakistan. For Pakistani adults who meet the eligibility profile, the available infusion locations are HTCs in the United States and in European Union countries where Roctavian is commercially available. The Pakistani-side institutional partners that handle pre-travel eligibility work-up, post-travel monitoring, and corticosteroid management are the major tertiary academic and private haematology centres.
The Hemophilia Patients Welfare Society Pakistan supports family education and logistics planning around the travel-and-infuse arc alongside the clinical institutions.
The travel-and-infuse logistics are demanding. The patient must travel to the certified centre, undergo final pre-infusion confirmation locally at that centre, receive the one-time intravenous infusion over approximately two hours (dose-volume dependent), and remain near the certified centre for weeks of post-infusion corticosteroid management and FVIII expression monitoring before returning to Pakistan. Reserve Meds coordinates the certified-centre booking, the patient and family travel logistics, visa documentation flagging where needed, and the handoff between the certified centre's haematology team and the Pakistani-side haematology team for post-travel monitoring.
Section 5. Real cost picture for Roctavian in Pakistan
- Drug cost. International self-pay patients get a written custom quote that covers the medicine and the full coordination, travel, infusion-centre, and post-infusion monitoring costs. Medicine price: quote on request. You get a written quote for your case before you commit.
- International logistics and travel. Frozen-product logistics from BioMarin to the certified centre run on validated dry-ice or deep-frozen shippers with continuous temperature monitoring; this cost is largely embedded in BioMarin's supply chain to the certified centre rather than in a separate international shipping line to Pakistan. The dominant travel-side line items are patient and immediate-family travel (international airfare, accommodation near the certified centre for the multi-week post-infusion monitoring window), local ground transport, visa processing (US B-2 medical-treatment visa or EU Schengen medical-treatment visa where applicable), and incidentals. Medicine price: quote on request. You get a written quote for your case before you commit.
- Pre-travel work-up and post-travel monitoring. AAV5 antibody testing at the FDA-approved companion test, FVIII inhibitor history confirmation, baseline liver function tests, and any imaging required at the Pakistani-side haematology centre. Post-travel weekly liver function tests during the corticosteroid taper, then tapering frequency over the first year, FVIII activity monitoring at protocol-defined intervals, hepatocellular carcinoma surveillance per HTC protocol, and bleeding-event tracking. These costs are paid to the Pakistani-side institution.
- Regulatory and coordination. DRAP documentation fees where applicable, Reserve Meds' coordination fee itemised separately on every firm quote.
Medicine price: quote on request. You get a written quote for your case before you commit. Each insurer assesses named-patient claims case by case, but a gene therapy is not a standard reimbursable line for any Pakistani insurer. BioMarin's US outcomes-based warranty and US copay assistance do not extend to international self-pay patients.
Section 6. Typical timeline for Roctavian in Pakistan
Roctavian timelines extend materially beyond the DRAP regulatory clock because the certified-centre pathway is the rate-limiting layer. We give you a written timeline estimate for your case before you commit. Certified-centre booking and BioMarin RoctavianConnect verification typically takes 4 to 12 weeks depending on the centre's capacity and the patient's documentation completeness. The certified-centre stay itself is several weeks, structured around the infusion day and the subsequent corticosteroid-managed monitoring window. Post-return monitoring in Pakistan runs for years. These ranges are typical, not promises.
Section 7. What your physician needs to provide
For Roctavian the documentation work is the most extensive in the Reserve Meds matrix because both the Pakistani-side haematology team and the BioMarin certified centre require comprehensive medical records. The Pakistani-side treating haematologist provides the patient identifier (CNIC), the severe hemophilia A diagnosis with FVIII activity confirmed less than 1 IU/dL, the FVIII inhibitor history confirmed negative through prior medical records (Bethesda titre history where available, not patient recall alone), the bleeding-event history and any prophylaxis regimen the patient is on (recombinant or plasma-derived FVIII, emicizumab), baseline liver function tests (ALT, AST, alkaline phosphatase, total bilirubin), any history of hepatic disease, hepatitis B or C status, HIV status with viral load if positive, and the rationale for selecting Roctavian over continued FVIII prophylaxis or emicizumab.
The AAV5 neutralising antibody titre on the FDA-approved companion test is a hard pre-gate; the result must be in hand and negative before any certified-centre booking is initiated. The Pakistani haematologist coordinates the sample collection and submission to the laboratory performing the FDA-approved test, with DRAP sample-shipment documentation supporting the cross-border movement where required. The corticosteroid management plan is structured around the BioMarin label, which prescribes a prophylactic or reactive corticosteroid regimen (typically oral prednisone or equivalent) initiated based on ALT trends and tapered over weeks to months, individualised by the certified centre and continued under the Pakistani haematologist's supervision after return. The Pakistani haematologist's PMDC license number is on every document; the certified centre's haematology team provides parallel documentation under their own institutional credentials. Pharmacovigilance reporting through the DRAP Pharmacovigilance Centre for the long-running post-infusion monitoring stays with the treating haematologist in Pakistan.
Section 8. Common questions about Roctavian in Pakistan
Will a private insurer cover this? Medicine price: quote on request. You get a written quote for your case before you commit. Each insurer assesses named-patient claims case by case, but coverage of a gene therapy is not standard practice in the Pakistani market. We do not promise coverage.
Does Sehat Sahulat cover Roctavian? Medicine price: quote on request. Every case gets a written custom quote before you commit. The funding path is cash-pay or family-pooled cash-pay, often supplemented by diaspora contribution from relatives in the Gulf, Europe, or North America.
Can I be infused in Pakistan? No. BioMarin does not support infusion outside a qualified Hemophilia Treatment Centre, and there are no qualified centres in Pakistan. The infusion takes place at a certified centre in the United States or European Union, with travel, accommodation, and weeks of post-infusion monitoring at the centre as a non-negotiable part of the pathway.
Will a letter from my haematologist in Pakistan be sufficient? The Pakistani haematologist's clinical documentation is essential for the pre-travel work-up and post-travel monitoring, and feeds the certified centre's eligibility verification. The certified centre's own haematology team performs final pre-infusion confirmation and runs the infusion-day care; the case is genuinely co-managed across borders.
What is the safety profile? The most common adverse reactions in the GENEr8-1 phase 3 trial were transient ALT elevation, headache, nausea, vomiting, fatigue, abdominal pain, and infusion-related reactions. The dominant safety signal is hepatic transaminase elevation requiring corticosteroid management. There is a theoretical long-term risk of hepatocellular carcinoma related to AAV vector integration; no causal cases have been reported in the trial programme, and the label requires long-term hepatic surveillance.
What is the durability picture? Roctavian is not pitched as a cure. GENEr8-1 follow-up published in NEJM and subsequent journal updates show that FVIII expression declines over time in many patients. At five years, 80.8 percent of participants remained off regular prophylaxis, and modelled median time-to-return-to-prophylaxis ranged from 6.4 to 16.1 years. The honest framing for Pakistani patients and families: meaningful but not permanent benefit for most, with a real possibility of returning to factor replacement therapy within a decade.
How does Roctavian compare to emicizumab (Hemlibra)? Standard of care alternatives are recombinant FVIII prophylaxis and emicizumab (Hemlibra, Roche/Genentech), a bispecific antibody dosed subcutaneously. Hemlibra is a long-running maintenance therapy, broadly available including in jurisdictions where Roctavian is not registered, and suitable for patients with inhibitors. Roctavian offers the prospect of multi-year freedom from prophylaxis dosing for eligible patients. The choice is the treating haematologist's; Reserve Meds does not steer the decision.
How does the Hemophilia Patients Welfare Society Pakistan fit in? HPWS Pakistan supports family education, peer-to-peer connection with other Pakistani families navigating advanced bleeding-disorder care, and logistics planning around the travel-and-infuse arc. Reserve Meds works with HPWS Pakistan and the patient-advocacy networks around the major haematology centres rather than in place of them; the clinical case stays with the treating haematologist and the certified centre.
Section 9. Where Reserve Meds fits in Roctavian cases
Reserve Meds is a US-based digital health company. We do not replace your haematologist, do not replace BioMarin's RoctavianConnect programme, do not replace the certified treatment centre, and do not replace DRAP or the Hemophilia Patients Welfare Society Pakistan. For Roctavian specifically, the orchestration we provide is eligibility verification coordination between the Pakistani-side haematologist and BioMarin's RoctavianConnect, AAV5 antibody testing logistics where the FDA-approved companion test is performed abroad, certified-centre booking and the parallel scheduling of pre-travel and travel logistics, support to the family on the travel-and-stay layer including funding coordination across diaspora-based relatives, and the documentation framework that hands off between the certified centre's haematology team and the Pakistani-side haematology team for post-travel monitoring. Operating notes that bind the coordinator: AAV5 neutralising antibody titre is a hard pre-gate; FVIII inhibitor history is confirmed from records not recall; infusion is at the certified centre, not in Pakistan; durability is framed honestly; no off-label use; no paediatric coordination; no coordination for patients with active hepatic disease without explicit treating-centre sign-off. Standard NPP coordination applies with the gene-therapy-specific operating notes above as binding.
Section 10. Next step
If your haematologist has identified Roctavian as a possible option for severe hemophilia A and you are based in Pakistan, the next step is to start your intake. We confirm eligibility within one business day, route the conversation to a structured pre-travel work-up, and align with your haematology centre on the documentation framework. Reserved for you.
This guide is informational, not medical or legal advice. The DRAP framework and the BioMarin certified-centre pathway both require licensed clinical judgment; Reserve Meds is the coordinator, not the prescriber or the infusion centre.